L-Theanine for Stress

Verdict: Weak, placebo-dominated evidence for stress

L-theanine shows only weak, inconsistent evidence for relieving stress: people often report feeling calmer, but the most rigorous trials find that benefit is no larger than placebo and is not matched by changes in objective stress hormones.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

The grade stays at weak (Tier C) because of a persistent gap between how people feel and what their biology shows. The best recent trial (PMID 38758503, a 4-week double-blind RCT at 400 mg/day, n=30) found perceived-stress scores fell about 18% on L-theanine, but they fell almost exactly the same amount on placebo, with no significant difference between groups and no change in cortisol. A 2019 RCT (PMID 31623400, 200 mg/day for 4 weeks) similarly improved self-rated scales such as STAI while salivary cortisol and IgA stayed flat, a disconnect the authors flagged themselves.

Objective signals exist but do not line up with the subjective ones. A single 200 mg dose (PMID 34562208, crossover, n=16) lowered salivary cortisol more than placebo (p<0.001) and raised alpha brain-wave activity, yet did not significantly reduce subjective anxiety during the stressor. So acute dosing moves the biology but not the feeling, while chronic dosing moves the feeling but not the biology, leaving the causal story incomplete. A 2024 systematic review (PMID 39633316, 11 RCTs) reported symptom relief in psychiatric populations, but stress-specific data in healthy adults were limited.

Regulators and clinics reinforce the caution. The US FDA treats L-theanine as safe ('FDA has no questions') but endorses no stress claim, and the EU EFSA concluded that 'a cause and effect relationship has not been established.' Cleveland Clinic says only that it 'may help promote relaxation and reduce stress' while noting limited human research. Three of the four trials were small and industry-funded, adding a conflict-of-interest caveat, so the verdict is published-with-warning rather than a recommendation.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.47
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
85%
Highly consistent evidence
Evidence level
E3
Single high-quality meta-analysis

How strongly each layer supports this effect

lower = less supportive
L2 PubMedPrimary literature
0.45
L3 MechanismPlausibility
0.45
L1 ExamineGlobal benchmark
0.50
L5 Clinical bodiesAuthoritative stance
0.55
L11 AI re-checkIndependent read
0.65
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.475
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (1 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Safety and Efficacy of AlphaWave® L-Theanine Supplementation for 28 Days in Healthy Adults with Moderate Stress: A Randomized, Double-Blind, Placebo-Controlled Trial
PMID: 38758503 2024 RCT (double-blind) n = 30
Finding: PSS reduced 17.98% in L-theanine arm at day 28 (p=0.04); placebo reduced 17.88% (p=0.009) - no significant between-group difference. No significant between-group cortisol differences. Stroop attention improved 21.33-21.79% in L-theanine arm; light sleep reduced vs placebo.
⚠️ Industry-funded Effect size: [object Object]
View on PubMed
A Randomized, Triple-Blind, Placebo-Controlled, Crossover Study to Investigate the Efficacy of a Single Dose of AlphaWave® l-Theanine on Stress in a Healthy Adult Population
PMID: 34562208 2021 RCT (double-blind) n = 16
Finding: Significantly greater salivary cortisol decrease 1h post-dose vs placebo (p<0.001); within-group cortisol -42.4% (L-theanine) vs -32.6% (placebo). Frontal alpha power increased 70.6% (p=0.038); whole-scalp alpha 109.0% (p=0.050). Subjective state anxiety/VAS showed no significant between-group difference post-dose.
⚠️ Industry-funded Effect size: [object Object]
View on PubMed
The effects of L-theanine supplementation on the outcomes of patients with mental disorders: a systematic review
PMID: 39633316 2024 系統性回顧
Finding: L-theanine reduced psychiatric symptoms more than control conditions in schizophrenia, anxiety disorders, and ADHD across 11 RCTs from 6 countries; authors call for further validation. Stress-specific data limited; mostly anxiety-related populations.
View on PubMed
Effects of L-Theanine Administration on Stress-Related Symptoms and Cognitive Functions in Healthy Adults: A Randomized Controlled Trial
PMID: 31623400 2019 RCT (double-blind) n = 30
Finding: Subjective measures improved: SDS (p=0.019), STAI-trait (p=0.006), PSQI (p=0.013). Objective biomarkers unchanged: salivary/serum cortisol and IgA showed no significant effect after 4 weeks. Authors explicitly note dissociation - psychotropic self-report effects did not translate to biological stress markers under chronic dosing.
⚠️ Industry-funded
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Supportive
FDA has no questions source↗
L4b EU EFSA
Against
a cause and effect relationship has not been established between the consumption of L-theanine from Camellia sinensis and improvement of cognitive function source↗
L4d TW TFDA / 衛福部
Neutral
茶氨酸為茶葉中天然存在之胺基酸成分 source↗
L5c Cleveland Clinic
Neutral
L-theanine may help promote relaxation and reduce stress source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-stress-INT-l-theanine-001 繁體中文版 →